Table of Contents
ISRN Psychiatry
Volume 2013, Article ID 546030, 5 pages
http://dx.doi.org/10.1155/2013/546030
Clinical Study

The Therapeutic Effect of Adding Dextromethorphan to Clonidine for Reducing Symptoms of Opioid Withdrawal: A Randomized Clinical Trial

1Clinical Psychiatry Research Center (CPRC), Tabriz University of Medical Sciences, Tabriz, Iran
2Department of Psychiatry, Razi Psychiatric Hospital, El Goli Boulevard, P.O. Box 5456, Tabriz, Iran
3Department of Pharmacology, Tabriz University of Medical Sciences, Tabriz, Iran

Received 9 May 2013; Accepted 11 June 2013

Academic Editors: W. El-Hage, V. Sar, T. Shibre, and H. P. Volz

Copyright © 2013 Ayyoub Malek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Mokri, “Brief overview of the status of drug abuse in Iran,” Archives of Iranian Medicine, vol. 5, no. 3, pp. 184–190, 2002. View at Google Scholar · View at Scopus
  2. S. M. Assadi, M. Hafezi, A. Mokri, E. M. Razzaghi, and P. Ghaeli, “Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial,” Journal of Substance Abuse Treatment, vol. 27, no. 1, pp. 75–82, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. M. S. Gold, D. E. Redmond Jr., and H. D. Kleber, “Clonidine blocks acute opiate-withdrawal symptoms,” The Lancet, vol. 1, no. 8090, pp. 599–602, 1978. View at Google Scholar · View at Scopus
  4. K. Raith and G. Hochhaus, “Drugs used in the treatment of opioid tolerance and physical dependence: a review,” The American Journal of psychiatry, vol. 154, no. 4, p. 584, 2004. View at Google Scholar
  5. H. Koyuncuoglu and B. Saydam, “The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chlorpromazine,” International Journal of Clinical Pharmacology Therapy and Toxicology, vol. 28, no. 4, pp. 147–152, 1990. View at Google Scholar · View at Scopus
  6. G. Gerra, A. Zaimovic, F. Giusti et al., “Noradrenergic and hormonal responses to physical exercise in adolescent: relationship to anxiety and tolerance to frustration,” Neuropsychobiology, vol. 27, no. 2, pp. 65–71, 1993. View at Publisher · View at Google Scholar
  7. G. Gerra, A. Zaimovic, F. Giusti et al., “Lofexidine versus clonidine in rapid opiate detoxification,” Journal of Substance Abuse Treatment, vol. 21, no. 1, pp. 11–17, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. I. H. A. Franken and V. M. Hendriks, “Predicting outcome of inpatient detoxification of substance abusers,” Psychiatric Services, vol. 50, no. 6, pp. 813–817, 1999. View at Google Scholar · View at Scopus
  9. S. H. Armenian, M. A. Chutuape, and M. L. Stitzer, “Predictors of discharges against medical advice from a short-term hospital detoxification unit,” Drug and Alcohol Dependence, vol. 56, no. 1, pp. 1–8, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. D. R. Wesson and W. Ling, “The clinical opiate withdrawal scale (COWS),” Journal of Psychoactive Drugs, vol. 35, no. 2, pp. 253–259, 2003. View at Google Scholar · View at Scopus
  11. B. J. Sadock and V. A. Sadock, Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Lippincot Williams & Wilkins, Philadelphia, Pa, USA, 7th edition, 2000.
  12. M. S. Gold, A. L. C. Pottash, D. R. Sweeney, and H. D. Kleber, “Efficacy of clonidine in opiate withdrawal: a study of thirty patients,” Drug and Alcohol Dependence, vol. 6, no. 4, pp. 201–208, 1980. View at Google Scholar · View at Scopus
  13. A. Kahn, J. P. Mumford, G. A. Rogers, and H. Beckford, “Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital,” Drug and Alcohol Dependence, vol. 44, no. 1, pp. 57–61, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. H. D. Kleber, C. E. Riordan, and B. Rounsaville, “Clonidine in outpatient detoxification from methadone maintenance,” Archives of General Psychiatry, vol. 42, no. 4, pp. 391–394, 1985. View at Google Scholar · View at Scopus
  15. G. Gerra, A. Marcato, R. Caccavari et al., “Clonidine and opiate receptor antagonists in the treatment of heroin addiction,” Journal of Substance Abuse Treatment, vol. 12, no. 1, pp. 35–41, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. B. KuKanich and M. G. Papich, “Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs,” Journal of Veterinary Pharmacology and Therapeutics, vol. 27, no. 5, pp. 337–341, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Zhu, S. Jenab, K. L. Jones, and C. E. Inturrisi, “The clinically available NMDA receptor antagonist dextromethorphan attenuates acute morphine withdrawal in the neonatal rat,” Developmental Brain Research, vol. 142, no. 2, pp. 209–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Bisaga, S. D. Comer, A. S. Ward, P. Popik, H. D. Kleber, and M. W. Fischman, “The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans,” Psychopharmacology, vol. 157, no. 1, pp. 1–10, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Bisaga, P. Gianelli, and P. Popik, “Opiate withdrawal with dextromethorphan,” American Journal of Psychiatry, vol. 154, no. 4, p. 584, 1997. View at Google Scholar · View at Scopus
  20. S. D. Comer and M. A. Sullivan, “Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers,” Psychopharmacology, vol. 193, no. 2, pp. 235–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Akerele, A. Bisaga, M. A. Sullivan et al., “Dextromethorphan and quinidine combination for heroin detoxification,” American Journal on Addictions, vol. 17, no. 3, pp. 176–180, 2008. View at Publisher · View at Google Scholar · View at Scopus